News | June 15, 2022
Eurocine Vaccines expands portfolio with a therapeutic HSV-2 vaccine candidate
Redbiotec has a right to royalties on Eurocine Vaccines´ net sales of an approved HSV-2 vaccine, should such sales arise.
Redbiotec has a right to royalties on Eurocine Vaccines´ net sales of an approved HSV-2 vaccine, should such sales arise.
Gilman will be responsible for all business development and portfolio strategy efforts globally.
The proposed transaction involves the sale of the global biosimilars portfolio of Viatris to Biocon Biologics
First and only FDA-approved device of its kind demonstrates consistently high rates of target limb salvage and freedom from clinically-driven target lesion revascularization
Acceptance based on results from the phase 3 KEYNOTE-091 trial
Strides was granted a Competitive Generic Therapy (CGT) designation for its ANDA.
Cantourage introduces second Clever Leaves medical cannabis product to the German market
Tislelizumab is now approved in nine indications in China
Centre of Excellence at Kharel comprises Skill-building Centre and Primary, Secondary and Higher Secondary schools
Plans to establish six state of the art TaCa Centre for Surgery in next 2 years in these states
Subscribe To Our Newsletter & Stay Updated
